Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections

Abstract Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One pati...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 71; no. 3; pp. 667 - 671
Main Authors Shields, Ryan K, McCreary, Erin K, Marini, Rachel V, Kline, Ellen G, Jones, Chelsea E, Hao, Binghua, Chen, Liang, Kreiswirth, Barry N, Doi, Yohei, Clancy, Cornelius J, Nguyen, M Hong
Format Journal Article
LanguageEnglish
Published US Oxford University Press 27.07.2020
Subjects
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Bacterial Proteins
beta-Lactamases
Boronic Acids
Brief Reports
Carbapenem-Resistant Enterobacteriaceae
Enterobacteriaceae Infections - drug therapy
Humans
Klebsiella pneumoniae - genetics
Meropenem - therapeutic use
Microbial Sensitivity Tests
meropenem
vaborbactam
porin
resistance
KPC
Online AccessGet full text

Cover

More Information
Summary:Abstract Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam–nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciz1131